- Home
- AREN vs AARD Comparison
AREN vs AARD Comparison
Compare AREN & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AREN
- AARD
- Stock Information
- Founded
- AREN 2016
- AARD 2017
- Country
- AREN United States
- AARD United States
- Employees
- AREN N/A
- AARD N/A
- Industry
- AREN Medical/Dental Instruments
- AARD Biotechnology: Pharmaceutical Preparations
- Sector
- AREN Health Care
- AARD Health Care
- Exchange
- AREN Nasdaq
- AARD Nasdaq
- Market Cap
- AREN 233.1M
- AARD 231.9M
- IPO Year
- AREN N/A
- AARD 2025
- Fundamental
- Price
- AREN $4.11
- AARD $10.98
- Analyst Decision
- AREN Strong Buy
- AARD Strong Buy
- Analyst Count
- AREN 1
- AARD 8
- Target Price
- AREN $12.00
- AARD $30.75
- AVG Volume (30 Days)
- AREN 206.7K
- AARD 169.3K
- Earning Date
- AREN 11-13-2025
- AARD 11-13-2025
- Dividend Yield
- AREN N/A
- AARD N/A
- EPS Growth
- AREN N/A
- AARD N/A
- EPS
- AREN 2.74
- AARD N/A
- Revenue
- AREN $146,610,000.00
- AARD N/A
- Revenue This Year
- AREN $29.48
- AARD N/A
- Revenue Next Year
- AREN $11.72
- AARD N/A
- P/E Ratio
- AREN $1.52
- AARD N/A
- Revenue Growth
- AREN 6.81
- AARD N/A
- 52 Week Low
- AREN $0.56
- AARD $4.88
- 52 Week High
- AREN $10.05
- AARD $19.58
- Technical
- Relative Strength Index (RSI)
- AREN 34.15
- AARD 46.68
- Support Level
- AREN $4.64
- AARD $9.34
- Resistance Level
- AREN $5.18
- AARD $11.51
- Average True Range (ATR)
- AREN 0.41
- AARD 0.87
- MACD
- AREN -0.09
- AARD 0.03
- Stochastic Oscillator
- AREN 5.97
- AARD 59.93
About AREN The Arena Group Holdings Inc.
The Arena Group Holdings Inc is a tech-powered media company that fuses technology, iconic brands, and marketing to deliver vibrant content and experiences that reach million users each month. The company creates robust digital destinations that delight consumers with powerful journalism, news about things such as favorite sports teams, advice on investing, the inside scoop on personal finance, and the latest on lifestyle essentials. The Company operates in one reportable segment which focuses on a publishing platform. The company generates revenue from Digital and Print, where the majority is generated from Digital. The company owns and operates TheStreet, The Spun, Parade, and Men's Journal and powers more than 320 independent Publisher Partners.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.